New Project Funded: Precision Therapy for Breast Cancer Using Comparative Oncology

We have been awarded a new project entitled “Development of Highly Specific and Potent Degrader-Antibody Conjugates for Triple Negative Breast Cancer Treatment” (Ref. LISBOA2030-FEDER-00918600).

This project aims to develop next-generation targeted therapies for triple-negative breast cancer (TNBC) by combining advanced antibody engineering with PROTAC technology. Using our rabbit-derived single-domain antibody platform we will create Degrader-Antibody Conjugates (DACs) with high precision and potency.

By integrating a comparative oncology approach with feline and human TNBC models, the project bridges veterinary and human medicine, paving the way for future clinical translation in both species